TOP NEWS and HEADLINES in September

  • Researcher Developing New Method for Hearing Loss Assessment
  • Test Drive the New BHI Hearing Loss Simulator
  • IHS Convention Opens in Reno
  • Med-El Announces First US Surgical Implants of SONATA Device
  • Oticon Women in Audiology Conference Held
  • 10 Reasons Children with Hearing Loss Do Not Use Hearing Aids
  • True Identity of Hair Cell Tip-Links Revealed
  • Neuromonics Launches First US Clinical Study on Tinnitus Treatment
  • Oticon Think Pink Edition Benefits Cancer Research in October
  • GN Otometrics Launches New Generation of Hi-Pro

  • According to a recent national online survey conducted by Siemens Hearing Instruments Inc, two thirds (66%) of consumers say that the recommendations of their hearing care professional are important when selecting a hearing instrument, and an overwhelming 85% of consumers who have been seen by a dispensing professional report satisfaction with their treatment.
  • Researchers at the Hebrew University of Jerusalem and elsewhere have identified the brain’s planum temporale as responsible for a key auditory process—perceiving the location of sounds, even when the listener is not concentrating on those sounds. Their findings appear in the September 20 issue of the journal Neuron.
  • The Callier Center for Communication Disorders at The University of Texas at Dallas (UTD) has established the annual Callier Prize in Communications Disorders. Nominations are now being accepted and a recipient will be chosen by March 2008. Accompanied by $10,000 in cash, the Callier Prize will recognize individuals for their leadership in fostering scientific advances in the diagnosis and treatment of communication disorders. The prize will rotate among recipients chosen from the fields of hearing, speech, and language, with the first winner coming from the field of audiology.
  • The discovery of the first anatomically modern ear in a group of 260-million-year-old fossil reptiles significantly pushes back the date of the origin of an advanced sense of hearing, and suggests the first known adaptations to living in the dark.
  • Current studies led by Richard Salvi, PhD, at the State University of New York at Buffalo, focus on the in-depth analysis of the effect of AHLi-11 and other molecules in preventing chemotherapy-induced hearing loss. Based on these studies, Quark Pharmaceuticals of Fremont, Calif, expects to file an IND within 2007 for AHLi-11 for the prevention of chemotherapy-induced hearing loss. AHLi-11 is a siRNA-based drug that temporarily inhibits the expression of human gene p53, which has been associated with cochlear hair cell apoptosis (cell death).
  • The results of a Finnish team of scientists suggest that auditory selective attention in humans cannot be explained by a gain model, where only the neural activity level is increased, but rather that selective attention additionally enhances auditory cortex frequency selectivity.
  • The Deafness Research Foundation (DRF) announced that its 2008 International Conference on Cell Replacement in the Inner Ear will be June 12-15, 2008, in Bethesda, Md.

Want the inside scoop? [register]Subscribe to HR’s FREE weekly e-newsletter, The HR INSIDER[/register].

Get Your Weekly Edition of THE INSIDER

Every week The Hearing Review sends out THE INSIDER, a weekly FREE e-newsletter devoted to the top hearing-related news, research, product introductions, fitting topics, and marketing research stories that are influencing your business or practice, as well as the industry at large. [register]Sign up[/register] for your free subscription now.